Quest Diagnostics is a prominent provider of diagnostic testing and related services, operating within the healthcare sector's diagnostics and research industry. The company offers a wide array of clinical testing, from routine to specialized services, alongside risk assessment and IT solutions, serving physicians, hospitals, health plans, and pharmaceutical companies through an extensive network. In its most recent reported quarters, Quest Diagnostics demonstrated a trend of exceeding analyst expectations for earnings per share. For Q4 2025, the company reported an actual EPS of $2.42 against an estimate of $2.45, and revenue of $2.806 billion against an estimate of $2.781 billion. Prior to this, Q3 2025 saw an actual EPS of $2.60 versus an estimate of $2.50, with revenue at $2.816 billion. This performance follows Q2 2025 where actual EPS was $2.62 against an estimate of $2.57, and Q1 2025 with actual EPS of $2.21 versus an estimate of $2.15. The company has shown a pattern of beating EPS estimates in the last four reported quarters, with revenue also generally meeting or exceeding expectations. Looking at the year-over-year trajectory, the reported earnings and revenues have shown an upward trend, with notable beats in EPS in Q3 2025 and Q2 2025. Recent news indicates that Evercore ISI has adjusted its price target for Quest Diagnostics to $210 from $220, maintaining an "In Line" rating, suggesting a tempered view on near-term potential, although institutional investors have increased their holdings. The company is scheduled to report its first-quarter earnings next month, with analysts forecasting a single-digit increase in EPS. Investors will be watching for continued EPS beats and revenue growth, as well as any guidance provided regarding future performance and the impact of market conditions on diagnostic demand.
